

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): **May 1, 2006**

**NEUROMETRIX, INC.**

(Exact name of registrant as specified in charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-50856**  
(Commission File Number)

**04-3308180**  
(IRS Employer  
Identification No.)

**62 Fourth Avenue**  
**Waltham, Massachusetts 02451**  
(Address of Principal Executive Offices) (Zip Code)

**(781) 890-9989**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

**Item 2.02 Results of Operations and Financial Condition.**

On May 1, 2006, NeuroMetrix, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2006. The full text of the press release and the related attachments are furnished as Exhibit 99.1 hereto and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of NeuroMetrix, Inc. dated May 1, 2006, including attachments.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEUROMETRIX, INC.

Dated: May 1, 2006

By:           /s/ Shai N. Gozani, M.D., Ph.D.  
Shai N. Gozani, M.D., Ph.D.  
President and Chief Executive Officer

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of NeuroMetrix, Inc. dated May 1, 2006, including attachments.

---

**NeuroMetrix, Inc. Reports Total Revenues of \$11.8 Million for the First Quarter 2006, 74% Growth over First Quarter 2005; GAAP Net Income of \$147,000, Non-GAAP Adjusted Net Income of \$885,000**

WALTHAM, Mass.—(BUSINESS WIRE)—May 1, 2006—NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the design, development and sale of proprietary products used to diagnose neuropathies, or diseases of the nerves, announced today the financial results for the three month period ended March 31, 2006.

Total revenues for the three months ended March 31, 2006, the Company's first quarter, were \$11.8 million, compared with \$6.8 million for the first quarter of 2005, representing an increase of 74%. During the three month periods ended March 31, 2006 and March 31, 2005, 87% and 88% of revenues, respectively, were derived from biosensor sales and 13% and 12% of revenues, respectively, were derived from diagnostic device sales.

The gross margin percentage for the first quarter of 2006 was 75.6% of revenues compared with 73.2% of revenues for the first quarter of 2005. In the first quarter of 2006, the gross margin percentage for biosensors was 74.9% of revenues compared with 73.3% of revenues in the first quarter of 2005. The gross margin percentage for diagnostic devices was 80.3% of revenues for the first quarter of 2006, compared with 73.0% of revenues for the first quarter of 2005.

Net income calculated in accordance with U.S. generally accepted accounting principles ("GAAP") for the first quarter of 2006 was \$147,000 compared with a net loss of \$(596,000) for the first quarter of 2005. Net income for the first quarter of 2006 and the net loss for the first quarter of 2005 included stock-based compensation expense of \$737,000 and \$76,000, respectively. The large increase in stock-based compensation expense was due to the adoption of Statement of Financial Accounting Standards No. 123R ("FAS 123R") in the first quarter of 2006. Excluding stock-based compensation expense, non-GAAP adjusted net income for the first quarter of 2006 was \$885,000 compared with a non-GAAP adjusted net loss of \$(520,000) for the first quarter of 2005.

Basic and diluted net income per share was \$0.01 for the three months ended March 31, 2006, compared with a basic and diluted net loss per share of \$(0.05) for the three months ended March 31, 2005. The basic and diluted net income (loss) per share for the three months ended March 31, 2006 and March 31, 2005 included stock-based compensation expense of \$737,000 and \$76,000, respectively. Non-GAAP adjusted basic and diluted net income per share was \$0.07 for the three months ended March 31, 2006 compared with non-GAAP adjusted net loss per share of \$(0.04) for the same period in 2005.

The following table contains a reconciliation of non-GAAP net income (loss), adjusted to exclude stock-based compensation expense, to GAAP net income (loss) and non-GAAP basic and diluted net income (loss) per share, adjusted to exclude stock-based compensation expense, to GAAP basic and diluted net income (loss) per share, during the first quarter of 2006 and 2005.

1

	<u>Three Months Ended March 31,</u>	
	<u>2006</u>	<u>2005</u>
<b>Net income (loss) reconciliation:</b>		
Net income (loss), as reported in accordance with GAAP	\$ 147,338	\$ (596,314)
Stock-based compensation expense	737,213	75,975
Non-GAAP adjusted net income (loss)	<u>\$ 884,551</u>	<u>\$ (520,339)</u>
<b>Net income (loss) per common share reconciliation:</b>		
Net income (loss) per common share, diluted, as reported in accordance with GAAP	\$ 0.01	\$ (0.05)
Stock-based compensation expense	0.06	0.01
Non-GAAP adjusted net income (loss) per common share, diluted	<u>\$ 0.07</u>	<u>\$ (0.04)</u>

Cash and cash equivalents and short-term investments totaled \$32.4 million as of March 31, 2006, compared with \$32.3 million as of December 31, 2005.

Shai N. Gozani, M.D., Ph.D., NeuroMetrix's President & CEO commented, "During the first quarter of 2006, we posted strong top line growth of 74% on a year over year basis due to continuing physician demand for our NC-stat neuropathy diagnostic solution. Our financial performance continued to be driven by growth in the primary care market, where we experienced an increase of 128% in biosensor usage on a year-over-year basis in the first quarter of 2006. We also experienced growth in the specialty care market, with an increase in biosensor usage of 32% year over year in the first quarter of 2006. We expanded our overall active customer count to a total of 3,639 physician practices and clinics, as of the end of the first quarter of 2006, compared with 2,424 at the end of the first quarter of 2005. There was a total of 255,500 biosensors used by our customers during the first quarter of 2006, an increase of 86% over the 137,600 biosensors used by our customers in the first quarter of 2005."

Dr. Gozani further commented: "In support of our long term goal of top line growth, we are in the process of expanding our sales force to a total of 46 regional sales managers. The hiring process was initiated in the fourth quarter of 2005 and is essentially complete. Our operating expenses increased in the first quarter of 2006 as a result of the expansion of our sales and marketing capabilities. We believe that the strengthening of our sales force will further advance our goal of creating a new standard of care throughout the marketplace."

**Company to Host Live Conference Call and Webcast**

The Company's management team will host a live conference call and webcast at 10:00 a.m. Eastern time on Monday, May 1, 2006 to discuss the Company's financial results for the three month period ending March 31, 2006. In addition, the Company may answer questions concerning business and financial

developments and trends, and other business and financial matters affecting the Company. The conference call may be accessed in the United States by dialing 1-888-396-2356 and using the confirmation code 49840293.

2

---

Internationally, the conference call may be accessed by dialing 617-847-8709, and using the same confirmation code. The webcast, along with the earnings press release and accompanying condensed financial statements, will be accessible from the Company's website at [www.neurometrix.com](http://www.neurometrix.com) under the "Investors" tab and a replay of the webcast will be available on the Company's website for twelve months. A replay of the conference call will be available starting two hours after the call by dialing 1-888-286-8010, domestically and 1-617-801-6888, internationally. The confirmation code to access the replay is 35941457. The replay will be available for three months following the conference call.

### **Non-GAAP Information**

In addition to disclosing results calculated in accordance with GAAP, the Company has also disclosed non-GAAP financial results that exclude stock-based compensation expense calculated under the requirements of FAS 123R and under certain additional accounting pronouncements. Management believes that these non-GAAP financial results provide useful information to investors regarding the financial performance of the Company and management believes that this non-GAAP financial information facilitates comparisons with historical financial results. Management uses these non-GAAP financial results for purposes of managing the business, planning, forecasting, determining compensation, for comparative purposes when assessing results versus peer companies and for other purposes. Given the importance of these non-GAAP financial results to the Company, the Company has disclosed this information to investors to facilitate an assessment of financial performance on the same basis as that applied by management. The Company feels that it is important for investors to understand the Company's financial results with and without the impact of the non-cash stock-based compensation expense resulting from the grant of stock options and other equity awards.

Non-GAAP information should not be viewed as a substitute for GAAP information. Investors and other users of the Company's financial statements should consider all information, including stock based compensation expense, when assessing the Company's financial performance. A reconciliation of GAAP to non-GAAP financial results has been included in tabular form in this press release.

### **About NeuroMetrix**

NeuroMetrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back and leg pain and carpal tunnel syndrome, as well as other clinical disorders. These clinical indications affect millions of patients in the United States. The NC-stat System, the Company's neuropathy diagnostic system, has been on the market since May 1999 and is presently used in over 3,600 physician's offices and clinics in the United States. The Company holds issued utility patents covering a number of important aspects of the NC-stat System.

3

---

The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the Company's or its management's expectations, hopes, beliefs, intentions or strategies regarding the future. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "plan" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on the Company's current expectations and beliefs concerning future developments and their potential effects on it. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with: dependence on the NC- stat System and its components; the Company's ability to increase its customer base and expand the market for its products; the ability to manage growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to the Company's customers for procedures performed using the NC-stat System; compliance with applicable quality control and manufacturing standards; retaining key management or scientific personnel; delays in the development of new products or to planned improvements to the Company's products; effectiveness of the Company's products compared to other medical device products; protection of the Company's intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; product liability lawsuits that may be brought against the Company; dependence upon computer and communication infrastructure utilized by the Company's products; the Company's capital and financing needs; and any failure of the Company to successfully integrate acquired businesses. These factors are discussed in more detail in the Company's filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT: NeuroMetrix, Inc.  
Bradford Smith, 781-314-2741  
Chief Financial Officer

NeuroMetrix, Inc.  
Condensed Statement of Operations  
(Unaudited)

	Three Months Ended	
	March 31, 2006	March 31, 2005
<b>Revenues:</b>		
Diagnostic device	\$ 1,541,437	\$ 812,400
Biosensor	10,281,838	5,977,364
<b>Total revenues</b>	<b>11,823,275</b>	<b>6,789,764</b>
<b>Cost of revenues</b>	<b>2,879,913</b>	<b>1,817,725</b>
<b>Gross margin</b>	<b>8,943,362</b>	<b>4,972,039</b>
<b>Operating expenses:</b>		
Research and development (1)	1,258,608	904,204
Sales and marketing (1)	5,268,253	3,244,651
General and administrative (1)	2,555,249	1,594,040
<b>Total operating expenses</b>	<b>9,082,110</b>	<b>5,742,895</b>
<b>Loss from operations</b>	<b>(138,748)</b>	<b>(770,856)</b>
Interest income	293,586	176,380
Interest expense	—	(1,838)
<b>Income (loss) before provision for income taxes</b>	<b>154,838</b>	<b>(596,314)</b>
Provision for income taxes	7,500	—
<b>Net income (loss)</b>	<b>\$ 147,338</b>	<b>\$ (596,314)</b>
<b>Net income (loss) per common share:</b>		
Basic	\$ 0.01	\$ (0.05)
Diluted	\$ 0.01	\$ (0.05)
<b>Weighted average shares used to compute net income (loss) per common share</b>		
Basic	12,414,479	12,043,103
Diluted	13,133,266	12,043,103

(1) Non-cash stock-based compensation expense included in these amounts is as follows:

Research and development	\$ 218,751	\$ 19,880
Sales and marketing	190,908	36,269
General and administrative	327,554	19,826
<b>Total non-cash stock-based compensation expense</b>	<b>\$ 737,213</b>	<b>\$ 75,975</b>

NeuroMetrix, Inc.  
Condensed Balance Sheets  
(Unaudited)

	March 31, 2006	December 31, 2005
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 5,395,753	\$ 8,170,037

Short-term held-to-maturity investments	26,971,891	24,081,946
Accounts receivable, net	5,576,502	4,543,339
Inventories, net	3,036,472	2,683,409
Prepaid expenses and other current assets	691,290	614,169
Current portion of deferred costs	249,496	223,009
<b>Total current assets</b>	<b>41,921,404</b>	<b>40,315,909</b>
Restricted cash	1,458,598	1,458,598
Fixed assets, net	935,832	875,551
Deferred costs	273,346	247,013
<b>Total assets</b>	<b>\$ 44,589,180</b>	<b>\$ 42,897,071</b>
<b>Liabilities and Stockholders' Equity</b>		
<b>Current liabilities:</b>		
Accounts payable	\$ 1,438,050	\$ 1,698,583
Accrued expenses	3,481,862	3,173,549
Current portion of deferred revenue	874,374	760,613
<b>Total current liabilities</b>	<b>5,794,286</b>	<b>5,632,745</b>
Deferred revenue	987,342	885,354
Other long-term liabilities	116,364	130,909
<b>Total liabilities</b>	<b>6,897,992</b>	<b>6,649,008</b>
<b>Stockholders' equity</b>		
Common stock	1,246	1,238
Additional paid-in capital	94,426,347	93,212,368
Deferred compensation	(343,823)	(425,623)
Accumulated deficit	(56,392,582)	(56,539,920)
<b>Total stockholders' equity</b>	<b>37,691,188</b>	<b>36,248,063</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 44,589,180</b>	<b>\$ 42,897,071</b>